This application seeks renewed CCSG funding for the City of Hope Comprehensive Cancer Center (COHCCC). The COHCCC brings together 131 Members from 34 Departments in the City of Hope Medical Center and the Beckman Research Institute. The Center receives $24,212,096M (Totals) from NCI, $25,947,483M from other peer-reviewed sources, and $31,421,929M from non-peer-reviewed sources, for a total of $81,581,508M in overall funding. Through faculty recruitment, reorganization, and significant infrastructure development, the COHCCC has greatly enhanced its ability to accelerate clinical and translational cancer-focused research. Seventy-two new faculty have been recruited, including 48 clinical investigators and 24 basic and population research scientists. The Cancer Center has five Programs: Molecular Oncology (MONC), Developmental Cancer Therapeutics (DCT), Cancer Immunotherapeutics (CI), Hematologic Malignancies (HM), and Cancer Control and Population Sciences (CCPS). Center membership has been honed to sharpen cancer focus and an Associate Member category has been created for investigators whose potential for peer-reviewed, cancer-focused research is yet developing. This application requests support for ten Shared Resources: Analytical Cytometry, Analytical Pharmacology, Bioinformatics, Functional Genomics/Genomic Sequencing, Pathology, Small Animal Imaging, Drug Discovery and Structural Biology, Survey Research, Biostatistics, and Clinical Protocol and Data Management. The COHCCC is primed to make significant advances in the coming years. Our 72 new basic, population and clinical research recruits will continue to introduce new ideas, technologies, and areas of research focus while enhancing the creative and innovative environment of the Center. Significant infrastructure and other resources have been created to facilitate the translation of discoveries to the rapid development of new cancer treatments, diagnostic tests, and other interventions that would aid people with cancer, as well as individuals at risk for malignancy. Finally, the overall configuration of the institution and its administrative capabilities in terms of leadership, programmatic alignment, development, and authority that have been augmented so that the Cancer Center will be more responsive to its members and to harness their collective energies and creativity. This proposal documents that the COHCCC has built a solid structure for achieving its missions and is stronger and more sustainable than it has ever been.
; Organizational capabilities under the authority of the Cancer Center Director are key for appropriate leadership, evaluation and planning. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.
|Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33|
|Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68|
|Salhotra, A; Tsai, N; Thomas, S H et al. (2015) Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50:139-41|
|Ali, H; Palmer, J; Eroglu, Z et al. (2015) Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant 50:307-9|
|Behrendt, Carolyn E; Hurria, Arti; Tumyan, Lusine et al. (2014) Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. J Natl Compr Canc Netw 12:1579-85|
|Yang, Lixin; Perez, Aldwin Apollo; Fujie, Sayuri et al. (2014) Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14:124|
|Gillis, Peter A; Hernandez-Alvarado, Nelmary; Gnanandarajah, Josephine S et al. (2014) Development of a novel, guinea pig-specific IFN-? ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-70|
|Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu et al. (2014) AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci 139:198-209|
|Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53|
|Sun, Virginia; Grant, Marcia; McMullen, Carmit K et al. (2014) From diagnosis through survivorship: health-care experiences of colorectal cancer survivors with ostomies. Support Care Cancer 22:1563-70|
Showing the most recent 10 out of 912 publications